ADC Therapeutics Faces FDA Concerns Over ZYNLONTA Combination While Reducing Losses
On August 13, ADC Therapeutics (NYSE:ADCT) reported mixed results in its second-quarter earnings call. The company confirmed that the Phase III LOTIS-5 trial for ZYNLONTA met primary efficacy goals but faced significant safety concerns from the FDA regarding a combination therapy with rituximab in treating second-line DLBCL, potentially delaying full approval. Despite regulatory hurdles, ADC Therapeutics reduced its net loss by 70% year-over-year to $16.6 million due to lower operating expenses and workforce reductions. The company ended Q2 with $219.1 million in cash, sufficient for operations through at least 2028. However, rising selling and administrative costs, along with increased interest expense from outstanding loans, remain a concern. The regulatory uncertainty has led to reduced institutional ownership and an increase in short interest (5.7% of the float), signaling bearish sentiment among investors.
Tickers: $ADCT